SF

Shinichiro Fuse

Partner/Managing Director at TPG Life Sciences Innovation

Cambridge, Massachusetts

Advisor

Invests in

  • Min Investment:

    $0.00

  • Max Investment:

    $0.00

  • Target Investment:

    $0.00

Skills

Biotechnology Industry
Lifesciences
Data Analysis
Business Strategy
Financial Modeling
Science
Entrepreneurship
Biotechnology
Assay Development
Start-ups
Strategy
Vaccines
Business Development
Leadership
Pharmaceutical Industry
Immunology
Oncology
Consulting
Life Sciences
Molecular Biology

Education

Lists including Shinichiro

AP
AO
AS
AN

Based in UK

1884 people

AM
AR
AB
AF

Based in Boston & Cambridge

668 people

AT
AS
AT
AH

All Series A Investors

14752 people

AM
AT
AS
AR

All Seed Investors

19695 people

AT
AE
AE
AL

All Pre-Seed Investors

7974 people

Investments

Sudo Biosciences

Series B

Total Funding: $180M

Santa Ana Bio

Series A

Total Funding: $170M

Orna Therapeutics

Seed

Total Funding: $320M

Triplet Therapeutics

Series A

Total Funding: $49M

Work Experience

T
TPG

2021

  • Partner/Managing Director

    2021

    Partner/Co-Lead, Life Sciences Innovations (LSI) Fund. Investments: Santa Ana Bio (Board), Sudo Biosciences (Board).

OT
Orna Therapeutics, Inc.

2019 - 2021

  • Board Member

    2020 - 2021

  • Interim CEO / Board Member

    2019 - 2020

    Circular RNA newco, MIT spinout (fka Oroboros)

E
ElevateBio

2017 - 2021

  • Advisor

    2019 - 2021

    Board observer

  • Founding/Interim Senior Vice President, Business Development

    2017 - 2019

    Led BD for ElevateBio (MPM newco) from launch - BD strategy, deal sourcing, diligence, transactions, establishment of Elevate subsidiaries, alliance management. Launched newcos/deals include AlloVir (fka Viracyte), HighPassBio, and other stealth newco's. Supported initial LifeEdit negotiations.

MC
MPM Capital

2016 - 2021

  • Managing Director

    2018 - 2021

    Life science venture capital & newco building. Investments: Orna (board + interim CEO), Triplet Therapeutics (board), ElevateBio (board observer), AlloVir (NASDAQ: ALVR), Repare Therapeutics (RPTX, board observer til IPO), CODA Biotherapeutics (board observer), iTeos Therapeutics (ITOS), 28-7, iOmx Therapeutics (board, starting 06/2020-), Crossbow

  • Principal

    2016 - 2018

bb
bluebird bio

2014 - 2016

  • Director, Business Development

    2015 - 2016

    Deal sourcing, diligence, negotiations, alliance management, strategy, and competitive intelligence. Lead/support on academic/corporate licenses/options, sponsored research, and M&A (Pregenen).

  • Senior Manager, Business Development

    2014 - 2015

CA
Campbell Alliance

2012 - 2014

  • Engagement Manager

    2013 - 2014

    Corporate Development team: Business development, corporate strategy, valuation, revenue forecasting, launch planning, indication prioritization.

  • Senior Consultant

    2012 - 2013

PV
PureTech Ventures

2011 - 2012

  • Associate

    2011 - 2012

    Founding & operational team of Vedanta Biosciences (microbiome) and Mandara Sciences (nutrition). Technology sourcing, due diligence, deal support, and newco building.

Clarion Healthcare

2008 - 2011

  • Consultant

    2009 - 2011

    Healthcare strategy consulting, primarily in oncology and immunology. Business development, corporate strategy, revenue forecasting, sales operations, launch planning.

  • Associate Consultant

    2008 - 2009

MS
Morgan Stanley

2007 - 2007

  • Summer Associate

    2007 - 2007

    Institutional Equities Division (Equity Research, Equity Sales & Trading). Industry and company analysis.